News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 217–252
- Matches
- 2118
- Sources here
- 17
- Companies here
- 22
Active search
2118 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
NCPL Looks 344.1% Overvalued on GF Value™
Netcapital Inc. (NCPL) is facing significant challenges, including an SEC investigation and a civil complaint, leading to its stock being considered 344.1% overvalued by GuruFocus's GF Value™ metric. The company has a low GF Score™ of 34/100 due to poor financial strength, profitability, and …
Crown Advisors Management Inc. Makes New Investment in FirstCash Holdings, Inc. $FCFS
Crown Advisors Management Inc. has made a significant new investment in FirstCash Holdings, Inc. ($FCFS), purchasing 40,000 shares valued at approximately $8.65 million, making it their sixth-largest holding. This comes as FirstCash exceeded its quarterly earnings and revenue expectations, reporting $2.50 adjusted EPS and …
HUTCHMED shares rise as lung cancer drug trial hits key targets
HUTCHMED shares rose by 4% after the biopharmaceutical company announced positive results from a late-stage global trial of its lung cancer drug, savolitinib. The Phase III SAFFRON study, testing savolitinib in combination with AstraZeneca's Tagrisso, met its main goal by showing statistically significant improvements …
Alberta Investment Management Corp Has $174.61 Million Stake in TC Energy Corporation $TRP
Alberta Investment Management Corp significantly reduced its stake in TC Energy Corporation ($TRP) by 34.1% in the second quarter, selling over 1.3 million shares. Despite this reduction, their remaining 2.6 million shares are valued at $174.61 million, making TC Energy its 9th largest holding. …
HUTCHMED Lung Cancer Combination Therapy Posts Phase III Win; Shares Surge Nearly 9% in Early Trading
HUTCHMED and AstraZeneca's combination therapy, ORPATHYS plus TAGRISSO, achieved significant improvements in progression-free survival and overall survival in the global SAFFRON Phase III study for non-small cell lung cancer patients. This marks the first global Phase III trial in this specific disease setting to …
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
HUTCHMED (China) Limited — First global Phase III trial to show significant progression-free and overall survival benefits in this setting — — SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., …
Sharemaestro market context New activity signal 52 weeks -24.4%After TAGRISSO, 338 lung-cancer patients tested a combination—what happened?
HUTCHMED's global Phase III SAFFRON trial showed that ORPATHYS® plus TAGRISSO® significantly improved progression-free and overall survival in patients with MET-driven EGFR-mutated advanced NSCLC after their disease progressed on TAGRISSO®. The combination's safety profile was consistent with known profiles of each medicine, with no …
HUTCHMED Reports Positive Phase III SAFFRON Results for ORPATHYS Plus TAGRISSO in EGFR-Mutated NSCLC
HUTCHMED announced positive results from the SAFFRON Phase III trial for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in EGFR-mutated non-small cell lung cancer (NSCLC) patients with MET overexpression or amplification. The combination significantly improved progression-free and overall survival compared to platinum-based chemotherapy. These results mark …
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks
This article identifies ETFs that hold HUTCHMED (China) Limited Sponsored ADR stocks, providing details such as market value, weight, issuer, expense ratio, and price changes. It highlights that ETFs make investing in stocks more accessible and offer opportunities with lower risk. The main fund …
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTC Therapeutics plans to acquire the ST-920 Fabry disease gene therapy asset for $111 million in a bankruptcy auction, with potential additional payments of up to $100 million based on U.S. regulatory milestones. This acquisition aims to leverage PTC's existing global commercial and regulatory …
333,702 Shares in PTC Inc. $PTC Purchased by SCS Capital Management LLC
SCS Capital Management LLC recently acquired 333,702 shares of PTC Inc. (NASDAQ:PTC), valued at approximately $37.9 million, making it their 20th largest holding. This purchase gives SCS Capital Management LLC about a 0.31% stake in the technology company. Despite PTC slightly beating EPS estimates …
Janney Montgomery Scott LLC Has $4 Million Holdings in TC Energy Corporation $TRP
Janney Montgomery Scott LLC reduced its stake in TC Energy Corporation (NYSE:TRP) by 47.1% in the second quarter, now holding 60,419 shares valued at approximately $4 million. Despite this, institutional investors collectively own 83.13% of the company. TC Energy exceeded earnings expectations, reported a …
One Wealth Advisors LLC Takes $2.06 Million Position in McGrath RentCorp $MGRC
One Wealth Advisors LLC has acquired a new position in McGrath RentCorp (NASDAQ:MGRC) worth $2.06 million during the second quarter, making it their 28th largest holding. Despite McGrath RentCorp missing its Q2 earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with an …
Costco's 48x Earnings Multiple Leaves No Margin for Error Despite Decade of Market-Beating Returns
Costco (COST) has demonstrated market-beating returns for decades, driven by its resilient membership model and strong sales growth, with July 2026 net sales up 10.7%. Despite this impressive performance, the stock trades at an approximately 48 times trailing earnings, an 86% premium to the …
Sharemaestro market context Price below Trend Line 52 weeks -1.4%Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT
Assenagon Asset Management S.A. significantly reduced its stake in PTC Therapeutics, Inc. by 88.8% in Q2, retaining 6,899 shares valued at $563,000, while other institutions like Segall Bryant & Hamill increased their positions. Despite insider selling worth $15.65 million, PTC Therapeutics reported strong Q2 …
Costco Wholesale Corporation $COST Shares Purchased by Baldwin Investment Management LLC
Baldwin Investment Management LLC increased its stake in Costco Wholesale Corporation (NASDAQ:COST) by 28.4% during the second quarter, making it their 10th largest holding. Several other institutional investors also adjusted their positions in COST. Despite a slight stock decrease, analysts maintain a "Moderate Buy" …
Erste Asset Management GmbH Purchases 7,007 Shares of Costco Wholesale Corporation $COST
Erste Asset Management GmbH increased its stake in Costco Wholesale Corporation by 42.2% in the second quarter, purchasing an additional 7,007 shares. The firm now owns 23,609 shares of Costco, valued at $22.297 million. Other institutional investors have also adjusted their positions, and analysts …
Sharemaestro market context Price below Trend Line 52 weeks -1.4%Costco brings back cult-favorite sweet treat discontinued in 2024, exciting shoppers
Costco has reintroduced its Kirkland Signature Semi-Sweet Chocolate Chips, which were discontinued in 2024 due to soaring cocoa prices. This return has excited shoppers, particularly Reddit users, who prefer these chips over more expensive alternatives like Ghirardelli and Guittard. The cocoa crisis, marked by …